IGFBP3 and non-small cell lung carcinoma: IGFBP3 expression was significantly down-regulated in cisplatin-resistant non-small cell lung cancer (NSCLC) cells, and overexpression of IGFBP3 enhanced the cisplatin response by blocking IGF1 signaling [20].